Faculty introduction, disclosures

Introductory content, screening, and diagnosis Epidemiology, including recent increase in incidence in young adults Common presenting symptoms among patients with early onset CRC Common presenting symptoms among patients with early onset CRC Multigene and next-generation sequencing tests

Treatment of mCRC  Treatment goals, with an emphasis on unresectable disease Brief overview of factors influencing the personalizing of systemic therapy, including: actionable biomarkers; previous therapy; and candidacy for intensive therapy Initial therapy HER2 amplification: consideration of anti-HER2 therapy with signal transduction inhibition vs. fluoropyrimidine ± bevacizumab Impact of RAS/BRAF V600E mutation, side (L/R) of primary tumor, and patient fitness on choice of cytoxic chemotherapy and bevacizumab Deficient MMR, MSI, or polymerase epsilon or delta mutations: checkpoint inhibitor immunotherapy MMR proficient, MSS Second-line therapy Previous therapy’s impact on treatment choice Next-line agents: treatment options after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF medication, and potentially an EGFR inhibitor (if RAS and BRAF wild-type) Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Recall factors impacting therapeutic decision-making in the treatment of mCRC, including biomarker and optimal sequencing considerations.
• Recall best practices in use of tumor genotyping for patients with mCRC.
• Describe the role of current pharmacotherapies for mCRC, their current or anticipated places in therapy, mechanisms of action, and risk-benefit profiles.
• Formulate a treatment plan for a patient with mCRC.

ACCME Activity #202837439

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Geoffrey Buckle, MD, MPH, Assistant Professor, Division of Hematology/Oncology, UCSF, has received financial compensation from VMLY&R, Tech.spert, Capvision, Alpha Insights, IDR, Athenum and Guidepoint for consulting.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.  

Faculty WILL NOT discuss off-label uses of a commercial product. 

All relevant financial relationships have been mitigated. 

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Merck. 

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version